LGSOC Awareness Day 2026: A New Patient Guide, and a Coalition That Refuses to Wait

Three years ago, low-grade serous ovarian cancer had no day of its own. No hashtag. No shared hub. Almost nothing written for patients in language they could actually use.

This September 9, the third annual LGSOC Awareness Day arrives with something that didn’t exist before: a free LGSOC Patient Resource Guide, written in plain language for the people living with this disease and the families trying to help them.

Nearly 20 nonprofits, advocacy groups, and research institutions built it together. You can download it at LGSOCAwarenessDay.org or right here on our site.

What started in 2024 as a single-organization effort has become a working network that shares volunteers, fundraising reach, and research contacts. All of it pointed at one goal.

The First Resource Guide Written for LGSOC Patients

Here’s a problem most LGSOC patients discover within days of diagnosis. You search your subtype, and what comes back is either a dense clinical paper or general ovarian cancer information that doesn’t quite fit your situation.

Low-grade serous behaves differently. It grows differently. It responds to treatment differently. Advice written for the most common form of the disease can send you down the wrong path entirely.

The LGSOC Patient Resource Guide exists to close that gap. It’s a plain-language handbook, free to download, covering what this specific subtype is and what navigating it actually involves. No paywall, no email gate, no medical dictionary required.

It was built almost entirely from the ground up by the patients and families the disease affects.

Why LGSOC Needs Its Own Movement

LGSOC accounts for roughly 2% to 5% of ovarian cancer diagnoses worldwide. Rare enough that it has historically received a fraction of the research attention and funding directed at more common cancers.

An estimated 65,000 people worldwide are living with it right now.

The numbers that matter most:

• Median age at diagnosis: 45. Compare that to 63 for high-grade ovarian cancer. LGSOC in young women means careers interrupted, fertility decisions forced early, and young children at home.
• Most patients are diagnosed at advanced stages. Slow growth sounds like good news. In practice it delays detection.
• Recurrence in advanced cases exceeds 80%. LGSOC recurrence is not the exception. It’s the expectation, which is exactly why long-term treatment options matter so much.

The disease differs from high-grade serous in its biology, its response to treatment, and its patient demographics. Those differences are precisely why general ovarian cancer research and awareness efforts haven’t served these patients well. If you want the side-by-side, our guide to LGSOC vs HGSOC breaks it down.

LGSOC symptoms include persistent bloating, pelvic pain, feeling full quickly, urinary urgency, and abdominal discomfort.

Read that list again. Every item on it sounds like something else. Stress. Diet. A bad month. And when the patient is 38 instead of 68, dismissal comes faster.

That pattern contributes directly to late-stage diagnoses, when treatment options narrow. If ovarian cancer bloating or pelvic pain has persisted for weeks and isn’t improving, that’s worth pushing on. Not next month. Now.

A Coalition Built by Patients

The organizations anchoring this movement look the way they do because patients built them.

STAAR Low-Grade Serous Ovarian Cancer Foundation was founded by three women diagnosed with LGSOC. It became the first U.S.-based nonprofit dedicated specifically to finding effective treatments for this cancer. Its volunteer board is half women living with the disease. STAAR established LGSOC Awareness Day in 2024 with support from Verastem Oncology.

Not These Ovaries was founded by Emily Campbell and her husband Chris after Emily’s borderline ovarian cancer diagnosis at 33. We started because we saw a gap that nobody was filling: the rare ovarian cancers affecting younger women had almost no research funding and not nearly enough treatment options.

“The momentum is coming from patients and ovarian cancer organizations who decided not to wait,” says Emily Campbell, founder and executive director of Not These Ovaries. “When we work together strategically, we can accelerate progress for people who need better resources now.”

The wider coalition includes the Sandy Rollman Ovarian Cancer Foundation, Michigan Ovarian Cancer Alliance, Sharsheret, the Ovarian Cancer Project, Let Every Woman Know–Alaska, Partnership to Reduce Cancer in Rhode Island, Tina’s Wish, National Ovarian Cancer Coalition, St. Louis Ovarian Cancer Awareness, Wisconsin Ovarian Cancer Alliance, LGSOC Initiative, Unite For HER, SHARE Cancer Support, Foundation for Women’s Cancer, Bay Area Cancer Connections, and the World Ovarian Cancer Coalition.

Several partners are expanding LGSOC-specific services this year. SHARE Cancer Support runs a Low-Grade Serous Ovarian Cancer Support Group facilitated by trained peers who have lived through the disease themselves. If you’ve been searching for people who understand your specific diagnosis, that’s a good place to start, and our roundup of ovarian cancer support groups covers more options.

Participating groups are hosting local events and initiatives across the United States throughout Ovarian Cancer Awareness Month.

Where LGSOC Treatment Actually Stands

Progress is real. It’s also incomplete.

The first FDA-approved treatment specifically for recurrent LGSOC arrived for patients with a KRAS mutation, a genuine milestone after decades of nothing. But that approval reaches a subset of patients. Many people with LGSOC still have no approved targeted option, which means clinical trials and off-label approaches carry enormous weight.

Standard chemotherapy is part of the picture, though chemotherapy for LGSOC tends to produce lower response rates than it does in high-grade disease. That’s one of the central frustrations of this subtype, and one of the clearest arguments for funding dedicated research.

How We Make an Impact

Not These Ovaries has supported studies on borderline ovarian tumors and low-grade serous ovarian cancer at Dana-Farber Cancer Institute, addressing the need for better surveillance and treatment options.

Donations established a dedicated Gynecologic Oncology Research Supervisor position at Mount Sinai Medical Center, a role that leads the institution’s low-grade ovarian cancer program and helps expand clinical trial capacity.

With STAAR, we awarded $115,580 to MD Anderson Cancer Center for research aimed at personalizing treatment for LGSOC patients.

Alongside the funding, we’re building the most comprehensive online resource for LGSOC and borderline tumors that exists anywhere. Because information gaps cost people time, and in this disease, time is the whole game.

How to Take Action on LGSOC Awareness Day

Download and share the guide. Send the LGSOC Patient Resource Guide to one person who needs it. A newly diagnosed patient, a caregiver, a gynecologist who could pass it along.

Visit LGSOCAwarenessDay.org. The central hub has donation options, volunteer sign-ups, downloadable social graphics, and connections to partner organizations near you.

Post using #LGSOCAwarenessDay. Awareness sounds soft until you trace where it leads. Awareness drives funding. Funding drives trials. Trials become the treatments that keep people alive.

Fund the research. Every dollar we raise goes directly to the science. Not to overhead, not to five-year timelines. To studies happening now.

The Changing LGSOC Landscape

A woman diagnosed with LGSOC this month walks into something different than she would have in 2023. There’s a day. There’s a coalition. There’s a guide written for her, in words she can read at the kitchen table without a medical degree.

None of that came from a large institution deciding this disease deserved attention. It came from patients who got tired of waiting.

There’s still an enormous amount of work ahead. Better detection. More approved treatments. Research funding that matches the burden this disease places on young women and their families.

But the direction is right, and the pace is picking up.

Join us on September 9. Visit LGSOCAwarenessDay.org, download the LGSOC Patient Resource Guide, and help make sure the next person diagnosed doesn’t have to start from nothing.

Every contribution, whether it’s sharing information, donating, or advocating for research, brings us closer to better treatments and earlier diagnoses. Together, we can improve outcomes for those affected by LGSOC and work towards a future where this disease no longer threatens lives.